The Oncology Institute (TOI) investor relations material

Industry context and challenges

• Oncology care represents over $200 billion in annual U.S. healthcare spend, with drug costs driving unsustainable growth for 16+ years.

• Patients face high out-of-pocket costs, often delaying or forgoing care, while payers struggle with rising specialty costs.

• There is a critical need for clinically excellent, community-based care that can reduce costs and improve access for underserved populations.

• Overutilization of off-label and non-guideline medications inflates costs, but adherence to NCCN guidelines in lower-cost settings can bend the cost curve.

• Partnerships with major health plans and risk-bearing groups have been maintained for over 15 years, reflecting quality and savings.

Differentiated care model and competitive landscape

• Operates as the largest value-based oncology provider, employing physicians and contracting with independent oncologists across 80 sites in five states.

• Unique model combines employed clinicians and engaged independents, enabling high compliance to value-based care and ancillary services like clinical trials.

• Competitors include benefits managers and care navigation models, but these lack direct control over care delivery and generate modest savings.

• Fee-for-service aggregators drive up rates and utilization, while this model offers full-spectrum services, including clinical trials and outpatient transfusions, to underserved populations.

• Attracts clinical trial sponsors by providing access to non-English speaking and economically underserved patients.

Outcomes, quality, and patient impact

• Delivers 100% NCCN-compliant care through proprietary pathways, updated in real time as new drugs are approved.

• Coordinates with hospice and palliative care, tracks KPIs on outcomes, patient experience, and quality, and is NCQA certified.

• Published studies and ASCO presentations demonstrate superior cost savings, patient satisfaction, and clinical outcomes compared to standard care.

• Internal data shows significant reduction in patient out-of-pocket costs, with over $1 million saved annually on Part D medications.

• High patient satisfaction is measured using Press Ganey methodology across thousands of visits.